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Background. Reductions in proximal reabsorption cause in-
creases in delivery of sodium chloride to the macula densa
(MD), which activates the tubuloglomerular feedback (TGF)
mechanism and reduces glomerular filtration rate. TGF under-
goes temporal adaptation, permitting filtration rate to rise in
spite of elevated MD delivery of NaCl. Inhibitors of nitric oxide
synthase I (NOS I) prevent TGF adaptation, but angiotensin-
converting enzyme inhibitors have no effect. COX-2 activity
moves in parallel with changes in NOS I and intrarenal renin.
We examined the impact of COX-2 inhibition on TGF tempo-
ral adaptation and effects of inhibition of COX-2 and NOS I on
plasma and kidney angiotensin II (Ang II).
Methods. Kidney blood flow (RBF) and glomerular filtra-
tion rate (GFR) were measured before and during benzolamide
(BNZ) infusion in control Wistar rats and rats concurrently re-
ceiving COX-2 inhibitors. Plasma and kidney angiotensin II
content was evaluated by radioimmunoassay in control rats,
rats after 60 minutes of BNZ, and during COX-2 and NOS-1
inhibition after BNZ.
Results. BNZ reduced both RBF and GFR in all groups. Dur-
ing BNZ, RBF and GFR returned to normal control values
within 60 minutes. COX-2 inhibitors totally prevented TGF
adaptation. Plasma and kidney Ang II did not change after
BNZ, and NOS I and COX-2 inhibitors had no effect on plasma
or intrarenal Ang II.
Conclusion. Within 1 hour after BNZ, rats undergo TGF
temporal adaptation. Administration of COX-2 inhibitors pre-
vented TGF temporal adaptation, identical to the effect of NOS
I inhibition. Changes in intrarenal Ang II cannot explain this
prevention of TGF temporal adaptation.
The efficacy by which the kidney maintains volume
homeostasis is based, in major part, on the capacity to
coordinate closely the rate of glomerular ultrafiltration
with tubular reabsorption. The processes of filtration and
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reabsorption are tightly inter-regulated through coordi-
nation of the process of glomerulotubular balance (GTB)
and tubuloglomerular feedback (TGF) [1]. The TGF sys-
tem, a conjunction of GTB and TGF, maintains stability
of the operating point against various perturbations, such
as surges in glomerular filtration rate (GFR) or inefficien-
cies in tubular reabsorption proximal to the macula densa
(MD). The TGF system operates acutely, but it is recog-
nized that the TGF system can adapt to new physiologic
realities over time. Such temporal adaptation of the TGF
system is required in order to permit the relationship of
late proximal tubular flow rate (VLP) to nephron filtra-
tion rate (SNGFR) to adjust appropriately, and maintain
homeostatic efficiency and operational relevance of the
overall TGF system.
A major focus of this laboratory has been the delin-
eation of mechanisms of temporal adaptation of the TGF
system. In early micropuncture studies, we either added
fluid to proximal tubular flow or inhibited proximal tubu-
lar reabsorption with the carbonic anhydrase inhibitor,
benzolamide (BNZ) [2–5]. We demonstrated that after
acute TGF activation there was temporal TGF adapta-
tion within 60 minutes, resulting in restoration of TGF
homeostatic efficiency via recruitment of increased vaso-
constrictor capacity. More recently, we have shown TGF
temporal adaptation after 24 hours of BNZ treatment,
resulting in supranormal values for GFR and SNGFR
after withdrawal of this agent [6]. These studies demon-
strated that TGF adaptation was not the result of primary
alterations in tubular reabsorption proximal to the MD,
but rather a major alteration in the relationship of the
MD signal to the temporally adapted SNGFR. In that
study, temporal TGF adaptations were associated with in-
creased expression of neuronal NOS (bNOS) within the
MD, and inhibitors of bNOS activity prevented tempo-
ral adaptation of TGF, thereby maintaining a decreased
SNGFR at values similar to acute TGF activation.
More recently, we have demonstrated that temporal
TGF adaptation of renal blood flow after BNZ normally
occurs within 60 minutes [2–4]. We have examined the
contribution of neurohumoral systems in this model and
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observed that angiotensin-converting enzyme (ACE) in-
hibitors did not prevent temporal adaptation of TGF [7].
However, administration of SMTC, a bNOS inhibitor,
completely prevented temporal adaptation, as observed
in the 24-hour studies. In more recent studies in the dia-
betic kidney, we have shown elevated renal bNOS activity
(independent from MD sources) and absence of tempo-
ral adaptation of TGF [8]. These results collectively lead
us to the conclusion that changes in bNOS activity af-
ter TGF activation are critical to temporal adaptation of
TGF, rather than any static level of bNOS activity.
The current study was designed to examine further the
mechanisms whereby changes in bNOS activity mediate
temporal adaptation of TGF. Logically, COX-2 enzyme
system is a candidate system that interacts with bNOS, al-
though the relationship is undoubtedly complex [9]. Our
results suggest that COX-2 inhibition also completely
prevents temporal adaptation of TGF in a manner iden-
tical to the application of bNOS inhibitors. These effects
of bNOS and COX-2 cannot be attributed to changes in
the kidney renin-angiotensin system.
METHODS
Animal experiments described herein were conducted
in accordance with the National Institutes of Health
Guide for the Care and Use of Animals in Research.
Physiologic studies on TGF adaptation
In the first study, two groups of male Wistar rats
(300-360 g; Harlan Labs, Indianapolis, IN, USA) were
used: (1) rats (N = 5) receiving continuous intra-
venous benzolamide (BNZ) infusion for 60 minutes;
and (2) rats given BNZ plus COX-2 inhibition (N =
6). BNZ was given to activate TGF [7]. BNZ de-
creases proximal tubular reabsorption by inhibition of
carbonic anhydrase, leading to an increased sodium de-
livery to the MD, which activates TGF [5]. Each rat was
anesthetized with Inactin (100 mg/kg IP; Research Bio-
chemicals, Natick, MA, USA), and a short section of
polyethylene tubing (PE-240) was inserted into trachea
to facilitate respiration. The left jugular vein was ex-
posed and cannulated with PE-50 tubing for infusion of
3H-inulin at a rate of 5 lCi/1.5 mL saline/hr, and for
infusion of BNZ and other drugs. A catheter (PE-50)
was placed in the left femoral artery for mean arterial
blood pressure (MABP) measurement and for blood
sample collection. The rat body temperature was main-
tained at 37◦C with servo-controlled heating table and
rectal temperature probe. An incision was made in the
abdomen, and PE-10 catheters inserted in the left ureter
for urine collections. The left kidney was exposed through
a flank incision. Blood flow (RBF) to the left kidney was
monitored by a perivascular ultrasonic transit time flow
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Fig. 1. Experimental protocol. Left renal blood flow was monitored
continuously and averaged over each measurement period. Glomeru-
lar filtration rate (GFR) was determined by inulin clearance in each
measurement period. BNZ infusion at time = 0 and CAY or SMTC
started 30 minutes before BNZ was prevented by COX-2 inhibition by
CAY. ∗P < 0.05 vs. control.
probe (Transonics T206, Ithaca, NY, USA) connected
to a computer for continuous recording [7]. GFR was
measured by 3H-inulin clearance. After 2-hour recov-
ery from surgery, rats in the BNZ only group underwent
two 25-minute control periods, followed by continu-
ous BNZ IV infusion (5 mg/kg IV bolus followed by
continuous IV infusion of 5 mg/kg/hr in 300 mmol/L
NaHCO3 at 1.3 mL/hr) for 60 minutes (Fig. 1). Rats
in the COX-2 inhibition group initially underwent a
20-minute control period, followed by a 30-minute con-
tinuous IV infusion of 3-(4-methylsulphonylphenyl)-4-
phenyl-5-trifluoromethylisoxaxole (CAY 10404; Cayman
Chemical, Ann Arbor, MI, USA), a selective COX-2 in-
hibitor, at 1.8 mg/kg/h, followed by addition of BNZ in-
fusion for 60 minutes. During BNZ infusion, the amount
of saline infused was adjusted to match the urine output.
In a second type of study, four groups of rats were used
for plasma and kidney tissue angiotensin II (Ang II) mea-
surements: (1) control group; (2) BNZ only group; (3)
BNZ + NOS I inhibition; and (4) BNZ + COX-2 in-
hibition. Rats in this group were submitted to identical
surgery as mentioned above, except that the abdomen re-
mained closed. After surgery, all rats underwent 2-hour
recovery. As shown in Figure 1, control rats received
saline infusion at 1.5 mL/hr for 110 minutes. The rats from
BNZ only group first underwent two 25-minute saline
infusion periods, followed by BNZ infusion for 60 min-
utes. The rats from BNZ + NOS inhibition underwent 20-
minute saline infusion, followed by 30-minute infusion of
S-methyl-thiocitrulline (SMTC, 2.7 mg/kg/hr; Alexis Bio-
chemicals, San Diego, CA, USA). At end of SMTC infu-
sion, BNZ was initiated and continued during SMTC for
60 minutes. The rats from BNZ + COX-2 inhibition un-
derwent 20-minute saline infusion, followed by 30-minute
CAY 10404, and then infusion of BNZ for 60 minutes.
At the end of the experiment an abdominal incision was
made and the kidneys were exposed, vessels clamped, and
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the kidney quickly removed and snap frozen in liquid ni-
trogen, and stored at −70◦C [7–11]. The abdominal aorta
was punctured, and blood was collected in a tube contain-
ing 15 lL of converting enzyme inhibitor (0.1 mmol/L)
per milliliter of blood. Samples were spun at 4◦C, and
plasma was stored at −70◦C until processed.
Angiotensin II radioimmunoassay
Plasma was extracted using a Bondelut C18 col-
umn (Varian, Harbor City, CA) previously washed
with methanol and a triethylamine and formic acid
buffer. The Ang II was eluted off with acetoni-
trile:triethylamine/formic acid (70/30), lyophilized on a
Speed-Vac (Savant, Farmingdale, NY, USA) overnight,
and kept at −20◦C until assayed [10, 11]. This plasma
extraction yielded 98.5% recovery of Ang II. Frozen kid-
neys were weighed, minced, added to 2 mL of radioim-
munoassay buffer, and polytroned for 10 seconds. This
solution was added to 9 mL of homogenizing buffer-1N
glacial acetic acid, 0.02N hydrochloride acid, and 0.1%
2-mercaptoethanol-(10% w/v) at 90◦C, and heated for
10 minutes, cooled, and centrifuged at 30,000g for 20 min-
utes. Supernatant was removed and saved on ice while
the pellet was re-extracted in 4.5 mL of homogenizing
buffer. The supernatants were combined and dried on a
Speed-Vac, and stored at −20◦C until ready for Bondelut
extraction, as described earlier for plasma samples. The
kidney recovery was 58%.
Lyophylisate was resuspended in 200 lL of radioim-
munoassay buffer. Specific rabbit Ang II antibody
(100 lL, Ab#127; provided by W. Vale, Salk Institute, La
Jolla, CA, USA) diluted 1/62,500 was added. After incu-
bating for 2 days at 4◦C, 100 lL of 125I-Ang II (6000 cpm)
(New England Nuclear, Boston, MA, USA) was added to
each tube and incubated again overnight [10, 11]. Ang II
bound to antibody was separated from unbound Ang II
using normal rabbit serum diluted 1/200 (100 lL), and
500 lL of 10% polyethylene glycol in radioimmunoas-
say buffer added to each tube. Tubes were incubated at
4◦C for 2 hours, spun for 30 minutes, the supernatant de-
canted, and the pellet counted in a gamma counter (Searle
model 1185, 80% efficiency; Searle, Peapack, NJ, USA).
Ang II concentrations were calculated using a computer-
aided logit/log transformation of the standard curve [11].
Cross-reactivity of this Ang II antibody with angiotensin
I is 0.33% and with angiotensin III is 69%.
Statistical analysis
Data are expressed as mean ± SEM; statistical com-
parisons were tested by Student t test and paired t test.
P values less than 0.05 were considered statistically
significant.
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Fig. 2. Left kidney blood flow (RBF) during benzolamide IV infusion
without (solid circles) and with COX-2 inhibition by CAY (open cir-
cles) (A). Benzolamide initiated at time 0. RBF was reduced after ben-
zolamide in both groups, indicating TGF activation. The reduced RBF
adapted to return to the control level over time in benzolamide alone
group. RBF adaptation was abolished by COX-2 inhibition with CAY.
∗P < 0.01 vs. control. Left kidney GFR before and during benzolamide
IV infusion without (solid circles) and with COX-2 inhibition by CAY
(open circles) (B). Benzolamide initiated at time 0. GFR was signifi-
cantly reduced after benzolamide in both groups, indicating TGF acti-
vation, and then gradually increased to the basal level in benzolamide
alone group in spite of continuous benzolamide infusion. The adaptive
GFR change after benzolamide was prevented by COX-2 inhibition by
CAY. ∗P < 0.05 vs. control.
RESULTS
Physiologic studies on TGF adaptation
We measured RBF and inulin clearances before and
during BNZ infusion for a period of at least 60 minutes
in the control group and a group that received COX-2
inhibitor. RBF was assessed continuously with a Doppler
flowmeter. Baseline values for RBF and GFR prior to
BNZ were not different, implying no major prior effects
of COX-2 inhibition (Fig. 2 and Table 1).
After BNZ, RBF and GFR decreased significantly at
20 minutes in both groups, and the reductions were of
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Table 1. Changes in RBF and GFR during BNZ infusion with or
without COX-2 inhibition
Periods I II III V
Time minutes −25 −5 20 60
RBFcontrol(mL/min) 6.80 ± 0.11 6.76 ± 0.08 5.88 ± 0.08b 6.94 ± 0.04
RBFCAY 7.15 ± 0.34 7.23 ± 0.23 5.87 ± 0.15b 5.90 ± 0.13b
GFRcontrol(mL/min) 1.28 ± 0.12 1.27 ± 0.11 0.81 ± 0.05a 1.26 ± 0.10
GFRCAY 1.31 ± 0.08 1.30 ± 0.08 0.99 ± 0.09b 0.95 ± 0.06b
Statistics were done by paired t test.
aP < 0.05 vs. II; bP < 0.01 vs. II.
similar magnitude in both groups. The decrease in GFR in
the COX-2 inhibitor group was quantitatively somewhat
less impressive. These reductions are the result of BNZ-
induced acute activation of TGF [5–7].
Resetting of the TGF response was assessed by com-
paring the measurements made during the first 20 to
60 minutes after BNZ. After the first 20 minutes of BNZ
infusion, both RBF and GFR trended upward to values
indistinguishable from pre-BNZ control values in the un-
treated group. However, in the group receiving COX-2
inhibitor, RBF and GFR remained at values identical to
the 20-minute values, reflecting a total absence of tem-
poral TGF adaptation (Fig. 2A and B and Table 1). The
response to BNZ during COX-2 (Fig. 2A and B) inhi-
bition is remarkably similar to our observations during
blockade of NOS 1 [7].
Plasma and kidney angiotensin II by radioimmunoassay
Both COX-2 and NOS 1 products have been suggested
to increase renin in the kidney. Both COX-2 and NOS 1
protein and in RNA increase on a low NACl diet and
various other high renin conditions. Because inhibition
of COX-2 and NOS 1 prevent temporal TGF adaptation,
we have utilized the same experimental model and eval-
uated changes in plasma and kidney Ang II by radioim-
munoassay to determine if prevention of TGF adaptation
correlates with changes in plasma and kidney Ang II
60 minutes after BNZ. Groups studied were (1) control
rats, (2) rats receiving only BNZ, (3) rats receiving BNZ
and treated with NOS 1 inhibitor, SMTC, and (4) rats
receiving BNZ and COX-2 inhibitor (Table 2). At least
two major points are obvious from these data. BNZ ad-
ministration does not produce changes in either plasma
or kidney Ang II. This implies that overall volume status
was well maintained during the period of TGF temporal
adaptation, and that changes in MD NaCl delivery were
not sufficient alone to alter kidney generation of Ang II.
Neither COX-2 nor NOS 1 inhibitors produced signifi-
cant changes in plasma or kidney Ang II content. The
values for kidney Ang II in SMTC group appeared quan-
titatively lower, but were not significant. After 24 hours
of BNZ [6], this form of TGF temporal adaptation was
associated with increased kidney Ang II, an event pre-
Table 2. Body weight, kidney weight, plasma angiotensin II, and
kidney angiotensin II levels in control, BNZ, BNZ+SMTC, and
BNZ+CAY groups
Kidney Plasma
Body Kidney Ang II Ang II
Groups weight g weight g pg/g KW pg/mL
Control (N = 6) 319 ± 1.5 1.35 ± 0.0848 247.67 ± 27.99 37.7 ± 3.0
BNZ (N = 5) 317 ± 2.0 1.35 ± 0.0495 359.52 ± 90.16 44.6 ± 4.2
BNZ+SMTC 319 ± 9.5 1.30 ± 0.0726 211.34 ± 25.82 34.8 ± 2.1
(N = 6)
BNZ+CAY 314 ± 1.3 1.33 ± 0.0555 330.23 ± 48.47 37.8 ± 2.9
(N = 7)
vented by SMTC (unpublished observations). We com-
pulsively replaced urinary losses during this period, and
no systematic volume alterations occurred in any group.
Weights were nearly identical (Table 2). In this short time
period model, changes in Ang II did not explain either
RBF or GFR differences with TGF adaptation, and did
not explain prevention of TGF adaptation by COX-2 in-
hibitors.
DISCUSSION
The potential physiologic and clinical importance of
the TGF system rests not only with the acute responses
to alterations in the MD NaCl signal, but also relates
to the capacity of the TGF system to adapt over time.
One could logically speculate that inability of the TGF
system to adapt temporally could have significant conse-
quences relating to GFR responses after tubular injury,
and could also lead to hypertension as a consequence of
abnormal NaCl retention by the kidney. It is therefore im-
portant to define the physiologic factors that contribute to
mechanisms underlying temporal adaptation of TGF. We
have provided evidence that increases in bNOS activity
are critical to the mechanism of temporal adaptation [6].
Any physiologic circumstance in which SNGFR and dis-
tal salt delivery change in the same direction must require
an elemental change in the behavior of TGF. Routine
examples include growth and development of the kid-
ney, pregnancy, changes in extracellular volume, changes
in cardiovascular dynamics, the nephron response to re-
duced renal mass, and others. Absence of such temporal
adaptations of TGF could obviously lead to major physio-
logic abnormalities. Understanding the regulatory mech-
anisms which mediate temporal adaptation of TGF is of
significant importance [4, 12].
MD NOS I is known to be an important modulator
of TGF, acutely [13, 14, 15], and selective inhibition of
NOS I amplified the acute TGF response, as indexed by
changes in glomerular capillary pressure [15]. In vitro
studies have also demonstrated significant increases in
MD cell NO by confocal microscopy when luminal NaCl
concentration is significantly increased [16]. Changes in
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activity of the enzyme have been shown to mediate the
longer-term temporal adaptation of TGF when BNZ is
administered for 24 hours [6]. Longer term suppression
of NOS I leads to sustained hypertension as a result of
NaCl retention secondary to a tonic leftward resetting of
the TGF response [17]. Factors regulating NOS I activ-
ity and expression then assume some importance to the
process of temporal adaptation.
NOS I and COX-2 protein expression in the kidney,
particularly in the MD, varies inversely with NaCl intake
in steady state and, therefore, change directly with renin
[9, 18, 21]. Angiotensin II also is purported to stimulate
NOS I expression independent of renin and NO genera-
tion [22]. Sensitivity to NOS I blockade is enhanced by
a high NaCl intake [21]. Inhibition of COX-2 and NOS
I enhance the vasoconstriction observed with TGF acti-
vation [15, 24]. Chronic TGF activation clearly increases
NOS I expression [6]. NO generated by MD NOS I atten-
uates acute TGF activation, and contributes to temporal
resetting, as well [7, 14]. These observations suggest that
the roles of NOS I in acute TGF activation and temporal
adaptation may be distinct, separable, and the interaction
highly complex.
COX-2 and NOS I exhibit capacities to increase renin
on a low NaCl diet [9, 21]. COX-2 activity requires the
intermediary activity of NOS I, and is prevented by
NOS I inhibitors [25]. During acute activation of TGF
by increased NaCl delivery to the MD, the ameliorating
influence of NOS I activity is mediated in part via activa-
tion of COX-2 enzyme and the consequent vasodilatory
products [24]. Therefore, one could conclude that NO
from NOS 1 both activates and increases expression of
COX-2, which, on a longer time scale, activates renin.
It is also possible that NOS I and COX-2 activities are
coordinated, but acting in parallel. It is logical to pre-
sume that the TGF temporal adaptation effects of NOS I
may involve the downstream participation of both COX-
2 activity and expression [9, 12, 26]. The net effects on the
renin-angiotensin system are potentially contradictory to
the acute effects of MD NaCl delivery and reabsorption.
Recent studies have provided further insights into this
complex interrelationship. Harris et al demonstrated that
NO derived from bNOS clearly increases COX-2 mRNA
and protein expression [9, 27]. bNOS inhibitors pre-
vented the increase in COX-2 mRNA and protein in
response to low NaCl diet and low NaCl plus capto-
pril, suggesting NO sits upstream from COX-2 at the
transcriptional/translational level. These collective stud-
ies do not relate specifically to the acute effects of NO on
COX-2 enzyme activity. More recent studies suggest that
deletion of either COX-2 and bNOS suppresses renin se-
cretion. Also, COX-2 products suppress expression and
activity of bNOS, indirectly suggesting that bNOS re-
mains “upstream” from COX-2 in the signal transduc-
tion sequence [28]. It seems reasonable to assume this
sequence would also apply to the process of temporal
adaptation of TGF.
Because both the COX-2 and bNOS systems are critical
to activation of the renin-angiotensin system and to tem-
poral adaptation of TGF, the role of the renin-angiotensin
system in TGF adaptation must be considered. In our
prior study, we demonstrated that pretreatment with an
ACE inhibitor did not prevent TGF temporal adaptation
[7]. The results of this study demonstrate that both in-
hibition of bNOS and COX-2 produce strikingly similar
results in preventing temporal adaptation of TGF. When
one steps back and views these results in the context of
the findings of those described above, the effects of inhi-
bition of bNOS and COX-2 on kidney Ang II generation
and temporal adaptation of TGF after BNZ are highly
interesting. In previous studies, we found that applica-
tion of NOS I inhibitors during 24 hours of BNZ treat-
ment effectively prevented TGF adaptation [6]. NOS I
inhibitors also prevented a BNZ induced increase in kid-
ney Ang II content after 24 hours of therapy, as one might
have predicted (unpublished observations). In the cur-
rent short-term model of TGF adaptation, we also ex-
amined the effects of BNZ and concurrent applications
of NOS I and COX-2 inhibitors on plasma and kidney
Ang II content to determine whether differences in kid-
ney Ang II might explain the finding of prevention of
TGF adaptation. Inhibition of COX-2 and bNOS pre-
vent renal vasodilatation and the increase in GFR, which
characterize TGF temporal adaptation. We observed in
the same model that BNZ did not increase Ang II kid-
ney content, and enzyme inhibition exerts no significant
effects on generation of Ang II during the time course of
TGF adaptation. These results suggest that COX-2 and
bNOS contributions to achieve temporal adaptation of
TGF cannot be attributed to suppression of Ang II ac-
tivity and kidney content. These findings imply that NOS
I and COX-2 produce bifurcated pathways for tempo-
ral adaptation via vasodilation while potentially increas-
ing Ang II, which should produce vasoconstriction. Does
this constitute some failsafe mechanism? If the renin-
angiotensin system were blocked, then one should see
accentuated temporal adaptation, a finding not observed
[7]. Possibly, the activation of renin limits the vasodilatory
action of NO and COX-2 products in some subtle fashion.
Clearly, changes in Ang II are not a factor contributing to
elimination of vasodilation and TGF adaptation follow-
ing blockade of NOS I and COX-2.
CONCLUSION
The current study demonstrates that inhibition of
COX-2 activity prevents the temporal adaptation of TGF.
These results are similar to those observed with bNOS
inhibition [6, 7]. It is likely that COX-2 acts in series
downstream from bNOS, but may act in parallel, as well.
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These agents normally activate renin; however, inhibition
of bNOS and COX-2 did not produce significant changes
in intrarenal Ang II after BNZ over the identical time pe-
riod of TGF adaptation. Inhibition of COX-2 and bNOS
can lead to NaCl retention and hypertension in some cir-
cumstances in spite of inhibition of renin secretion [17,
20]. Absence of temporal adaptation of TGF may pro-
vide a significant contributing mechanism to the observed
NaCl retention observed with these agents by produc-
ing relatively lower values for GFR at any given volume
status.
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